FDA ’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma Trials

In a 12 to 0 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) decided that evidence supported that minimal residual disease (MRD) could be used as an accelerated approval end point in clinical trials of multiple myeloma. “I think the sets a precedence of actually moving the field forward,…#fda #odac #mrd #ranjanahadvani #saulrosenberg #nicolegormley #approval #bindukanapuru #kanapuru #colalandgren
Source: Reuters: Health - Category: Consumer Health News Source Type: news